KCT0000199招募中未知
A Randomized, Double-blind, Placebo-controlled, Fixed dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients with Premature Ejaculation
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- Symyoo
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- Male
入选标准
- •1.Informed consent for subjects and partners
- •2.Men 20-65 ages
- •3.Stable monogamous relation at least for 6 mo
- •4.Premature Ejaculation Diagnosis Tool (PEDT) more than 9
- •5.At least 6 mo of premature ejaculation Hx
- •6.IELT of =< 2 min in >= 75% of evaluable events during 4 week screening period
排除标准
- •1History of medical or psychiatric illness
- •2.Erectile dysfunction (<21 International Index of Erectile Function-3.Erectile Function (IIEF-EF) domain score) or other forms of sexual dysfunction
- •4.Partner sexual dysfunction
- •5.Known hypersensitivity to clomipramine and contraindications for clomipramine
研究者
相似试验
招募中
1 期
A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics ofSingle Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects with Chronic Hepatitis C Genotype 1 Infection.Chronic Hepatitis C infectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612000176864CPR Pharma Services78
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, Hospitalized Patients, Study to Assess Efficacy and Safety of HP-3070 in Subjects with SchizophreniaSchizophreniaEUCTR2015-005134-21-SKoven Pharmaceuticals, Inc.617
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, With Open-Label ExtensioAdjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset SeizuresMedDRA version: 6.1Level: PTClassification code 10010145EUCTR2005-001338-33-ITJANSSEN-CILAG240
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-23 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, With Open-Label Extension - Topiramate Infant Partial Onset EpilepsyPartial Onset Epilepsy and other SeizuresEUCTR2005-001338-33-GBJanssen-Cilag International N.V.239
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, With Open-Label Extension - Topiramate Infant Partial Onset EpilepsyEUCTR2005-001338-33-CZJanssen-Cilag International N.V.240